Big Health, a digital therapeutics company, has recently raised an impressive $24 million in funding. This news has sparked excitement and optimism in the digital health industry, as investors strongly believe that the time for digital therapeutics has finally arrived.
Digital therapeutics, also known as Digiceuticals, are a new form of healthcare that uses technology to prevent, manage, or treat medical conditions. These digital treatments are delivered through devices such as smartphones, computers, and wearables, making them accessible to a wider audience. With the ever-increasing use of technology in our daily lives, it was only a matter of time before it made its way into the healthcare sector.
Big Health, founded in 2010 by Peter Hames and Professor Colin Espie, is at the forefront of this innovative field. The company’s flagship product, Sleepio, is a digital program designed to help individuals struggling with insomnia. Sleepio uses evidence-based cognitive and behavioral techniques to improve sleep and reduce symptoms of anxiety and depression. The program has already shown promising results, with 76% of users reporting improved sleep after using Sleepio.
The recent $24 million funding round was led by Gilde Healthcare, with the participation of existing investors, including Kaiser Permanente Ventures and Octopus Ventures. This significant investment is a testament to the growing demand for digital therapeutics and Big Health’s potential to lead the way in this emerging market.
The funds will be used to expand the reach of Sleepio and develop new products in areas such as anxiety, depression, and chronic pain. This expansion will not only benefit individuals struggling with these conditions but also healthcare systems, as digital therapeutics have the potential to reduce healthcare costs and improve patient outcomes.
Big Health’s success is not just a one-time occurrence. The digital therapeutics market is estimated to reach $9.4 billion by 2025, with a compound annual growth rate of 23.8%. This growth is driven by the increasing prevalence of chronic diseases, the rising adoption of smartphones and wearables, and the need for more cost-effective healthcare solutions.
One of the major reasons for the rapid growth of digital therapeutics is the increasing acceptance and support from healthcare professionals. With the rise of telemedicine and virtual care, healthcare providers are more open to incorporating digital therapeutics into their treatment plans. In fact, a recent survey found that 87% of physicians believe that digital therapeutics will play a significant role in patient care in the next five years.
Furthermore, the COVID-19 pandemic has highlighted the importance of digital health solutions. With physical distancing measures in place, many individuals have turned to digital therapeutics for support with their mental health. This has led to a surge in demand for these services, further accelerating the growth of the digital therapeutics market.
In addition to the support from healthcare professionals, digital therapeutics have also gained recognition from regulatory bodies. In 2018, the Food and Drug Administration (FDA) approved the first prescription digital therapeutic for the treatment of substance use disorder. This paved the way for more digital therapeutics to receive regulatory approval, giving them more credibility and opening up opportunities for growth and partnerships.
The recent funding raised by Big Health is not just a win for the company, but for the entire digital therapeutics industry. It is a sign of the industry’s potential and the trust that investors have in this new form of healthcare. With the right support, digital therapeutics have the potential to revolutionize the way we approach and manage medical conditions.
In conclusion, the $24 million investment in Big Health is a significant milestone for the digital therapeutics industry. It highlights the growing demand and acceptance of digital therapeutics and sets the stage for future growth and innovation. As digital health continues to evolve and integrate into traditional healthcare, the potential for digital therapeutics is limitless. The time for digital therapeutics has indeed arrived, and Big Health is leading the way.